Leonard Wossnig

Leonard Wossnig is the Chief Technology Officer at LabGenius, where innovative antibody discovery merges synthetic biology, robotic automation, and machine learning. Under Wossnig's leadership, LabGenius is advancing a pipeline of immunotherapies for solid tumors and has released research on immune cell engagers. Wossnig holds multiple roles, including Fellow of the Royal Society of Biology and Scientific Advisor at Shift Bioscience. Previously, Wossnig served as Vice President of Artificial Intelligence at Odyssey Therapeutics and co-founded Rahko, leading the company to its acquisition. Wossnig has an extensive academic background, culminating in a PhD from UCL and experience as a teaching assistant in various computer science courses.